<journal article>
The Application of Splenectomy to Decompress Portal Pressure in Left Lobe Living Donor Liver Transplantation

Creator
Language
Publisher
Date
Source Title
Vol
Issue
First Page
Last Page
Publication Type
Access Rights
JaLC DOI
Related DOI
Related URI
Related HDL
Abstract This study was conducted to evaluate the impact of splenectomy in living donor liver transplantation (LDLT) using left lobe grafts. The two hundred and fifty LDLT cases were divided into two groups : ...Group-S (n = 98, simultaneous splenectomy) and Group-NS (n = 152). Group-S had significantly increased recipient age (54.5 ± 10.9 years vs. 46.3 ± 17.0 years, p < 0.01), advanced liver diseases including Child class C (64.8% vs. 51.5%, p < 0.01), higher model for end-stage liver score (17.8 ± 8.1 vs. 15.4 ± 5.8, p < 0.01) and more patients with hospitalized status (67.4% vs. 48.0%, p < 0.01), and smaller graft volume/standard liver volume ratio (36.5 ± 6.1% vs. 40.2 ± 8.2%, p < 0.01). In Group-S, splenectomy decreased portal venous (PV) pressure decreased from 23.5 ± 5.2 mmHg to 19.2 ± 4.8 mmHg (p < 0.01). Group-S had significantly increased PV pressure at laparotomy (24.9±5.3 mmHg vs. 22.5 ± 6.3 mmHg, p < 0.01) and decreased PV pressure at closure (16.4 ± 3.5 mmHg vs. 18.0 ± 4.7 mmHg, p < 0.01), compared with Group-NS. On the 14th day after LDLT, Group-S had lower total bilirubin (5.7 ± 6.5 mg/dl vs. 8.7 ± 8.9 mg/dl, p < 0.01) and smaller ascites output (0.4 ± 0.7 L/day vs. 0.7 ± 0.4 L/day, p = 0.01) than Group-NS. The cumulative 5-year graft survival rate was 86.8% in Group-S and 76.2% in Group-NS (p = 0.03). In conclusion, splenectomy had beneficial impacts on graft outcomes in left-lobe LDLT.
【はじめに】生体肝移植に於いて, 左葉グラフトを使用することはドナーの安全性をより高める意味で重要であるが, グラフトサイズが小さいことによりグラフト機能不全そしてグラフト不全に繋がる可能性も秘めている. 我々は,摘脾を行うことで左葉グラフト移植をより安全に行う試みを行っている. 【対象および方法】対象は左葉グラフトを用いた生体肝移植250 例とした. 摘脾群(n=98)および非摘脾群(n=152)の二群に分類し, 背景因子, 手術・術後因子, そしてグラフト生存に関する比較検討を行った. 【結果】摘脾群は非摘脾に比し, 有意にレシピエント年齢が高齢(54.5 歳vs. 46.3 歳, p < 0.01), Child C 症例が多く(64.8% vs. 51.5%, p < 0.01), model for end-stage liver スコアが高値(17.8 ± 8.1 vs. 15.4 ± 5.8, p < 0.01), そしてグラフト標準肝容積比が小さい(36.5 ± 6.1% vs. 40.2 ± 8.2%, p < 0.01)症例群であった. 摘脾群では摘脾により門脈圧が有意に低下(23.5 ± 5.2mmHg to 19.2 ± 4.8mmHg, < 0.01)した. また, 摘脾群は非摘脾群に比し有意に開腹時門脈圧が高値(24.9 ± 5.3mmHg vs. 22.5 ± 6.3mmHg, p < 0.01)であったが, 閉腹時門脈圧は低値(16.4 ± 3.5mmHg vs. 18.0 ± 4.7mmHg, p < 0.01)であった. そして術後14 日目の総ビリルビン値および腹水排出量は摘脾群が非摘脾群に比し, それぞれ有意に低値(5.7 ± 6.5mg/dl vs. 8.7 ± 8.9mg/dl, p < 0.01), 少量(0.4 ± 0.7L/day vs. 0.7 ± 0.4L/day, p=0.01)であった. そしてグラフトの5年生存率は摘脾群(86.8%)が非摘脾群(76.2%)に比し有意に良好であった(p=0.03). 【まとめ】左葉を用いた生体肝移植に於いて, 摘脾を行うことはグラフト機能を改善するうえで有用な手段であると考えられた.
show more

Hide fulltext details.

pdf p282 pdf 1.03 MB 582  

Details

PISSN
NCID
Record ID
Peer-Reviewed
Related PubMed ID
Subject Terms
Type
Created Date 2014.01.21
Modified Date 2021.07.28

People who viewed this item also viewed